SI1702618T1 - Use of et743 in combination therapy with dexamethasone for treating cancer - Google Patents

Use of et743 in combination therapy with dexamethasone for treating cancer

Info

Publication number: SI1702618T1
Authority: SI; Slovenia
Prior art keywords: dexamethasone; combination therapy; treating cancer; cancer; treating
Prior art date: 1999-05-13

Application number

SI200030977T

Other languages

Slovenian (sl)

Inventor

Esteban Cvitkovic

George Daniel Dept Of Demetri

Cecilia Pharma Mar S A Guzman

Jose Pharma Mar S A U Jimeno

Lazaro Luis Pharma Mar S Lopez

Jean-Louis Service D On Misset

Chris University Of Gl Twelves

Hoff Daniel D Arizona Canc Von

Original Assignee

Pharma Mar Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-13

Filing date

2000-05-15

Publication date

2008-02-29

1999-05-13 Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en

1999-05-14 Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en

1999-08-05 Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en

1999-11-15 Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en

1999-11-16 Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en

2000-03-29 Priority claimed from GB0007637A external-priority patent/GB0007637D0/en

2000-05-15 Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa

2008-02-29 Publication of SI1702618T1 publication Critical patent/SI1702618T1/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)

SI200030977T 1999-05-13 2000-05-15 Use of et743 in combination therapy with dexamethasone for treating cancer SI1702618T1 (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
GBGB9911183.3A GB9911183D0 (en)	1999-05-13	1999-05-13	Treatment of cancers
GBGB9911346.6A GB9911346D0 (en)	1999-05-14	1999-05-14	Treatment of cancers
GBGB9918534.0A GB9918534D0 (en)	1999-08-05	1999-08-05	Treatment of cancers
GBGB9927005.0A GB9927005D0 (en)	1999-11-15	1999-11-15	Treatment of cancers
GBGB9927106.6A GB9927106D0 (en)	1999-11-16	1999-11-16	Cancer treatment
GB0007637A GB0007637D0 (en)	2000-03-29	2000-03-29	Antitumour compound
EP06011784A EP1702618B1 (en)	1999-05-13	2000-05-15	Use of et743 in combination therapy with dexamethasone for treating cancer

Publications (1)

Publication Number	Publication Date
SI1702618T1 true SI1702618T1 (en)	2008-02-29

Family

ID=27546594

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SI200031067T SI1716853T1 (en)	1999-05-13	2000-05-15	Treatment of cancers of the human body using ET743
SI200030905T SI1176964T1 (en)	1999-05-13	2000-05-15	Uses of et743 for treating cancer
SI200030977T SI1702618T1 (en)	1999-05-13	2000-05-15	Use of et743 in combination therapy with dexamethasone for treating cancer

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
SI200031067T SI1716853T1 (en)	1999-05-13	2000-05-15	Treatment of cancers of the human body using ET743
SI200030905T SI1176964T1 (en)	1999-05-13	2000-05-15	Uses of et743 for treating cancer

Country Status (32)

Country	Link
US (1)	US8119638B2 (en)
EP (3)	EP1176964B8 (en)
JP (2)	JP2002544231A (en)
KR (1)	KR20020019914A (en)
CN (2)	CN100477993C (en)
AR (1)	AR028476A1 (en)
AT (3)	ATE500830T1 (en)
AU (2)	AU777417B2 (en)
BG (1)	BG65680B1 (en)
BR (1)	BR0010531A (en)
CA (1)	CA2373794C (en)
CY (4)	CY1105818T1 (en)
CZ (1)	CZ301482B6 (en)
DE (4)	DE122008000013I1 (en)
DK (3)	DK1716853T3 (en)
ES (2)	ES2294756T3 (en)
FR (1)	FR08C0013I2 (en)
HU (2)	HU229866B1 (en)
IL (2)	IL146434A0 (en)
LU (1)	LU91418I2 (en)
MX (1)	MXPA01011562A (en)
MY (1)	MY164077A (en)
NL (1)	NL300337I2 (en)
NO (2)	NO324564B1 (en)
NZ (1)	NZ515423A (en)
PL (1)	PL198185B1 (en)
PT (3)	PT1716853E (en)
SI (3)	SI1716853T1 (en)
SK (1)	SK287580B6 (en)
TR (1)	TR200103819T2 (en)
UA (1)	UA74782C2 (en)
WO (1)	WO2000069441A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY164077A (en)	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
MXPA02011319A (en)	2000-05-15	2003-06-06	Pharma Mar Sa	Antitumoral analogs of et 743.
BR0115162A (en) *	2000-11-06	2003-10-21	Pharma Mar Sa	Effective antitumor treatments
GB0117402D0 (en) *	2001-07-17	2001-09-05	Pharma Mar Sa	New antitumoral derivatives of et-743
EP1435988A4 (en) *	2001-10-19	2008-01-09	Pharmamar Sa	Improved use of antitumoral compound in cancer therapy
GB0202544D0 (en)	2002-02-04	2002-03-20	Pharma Mar Sa	The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) *	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
GB0324201D0 (en) *	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
PT1689404E (en) *	2003-11-13	2008-12-15	Pharma Mar Sau	Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
US20080255132A1 (en) *	2003-11-14	2008-10-16	Eric Rowinsky	Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
JP2008505862A (en) *	2004-07-09	2008-02-28	ファルマ、マール、ソシエダード、アノニマ	Prognostic molecular marker
PL1827500T3 (en) *	2004-10-26	2009-09-30	Pharma Mar Sa	Pegylated liposomal doxorubicin in combination with ecteinescidin 743
DK1658848T3 (en) *	2004-10-29	2007-11-26	Pharma Mar Sa	Formulations comprising ecteinascidin and a disaccharide
GB0522082D0 (en) *	2005-10-31	2005-12-07	Pharma Mar Sa	Formulations
EP2023931A2 (en) *	2006-05-12	2009-02-18	Pharma Mar S.A.	Anticancer treatments with a combination of docetaxel and ecteinascidin
AU2008313634A1 (en) *	2007-10-19	2009-04-23	Pharma Mar, S.A.	Prognostic molecular markers for ET-743 treatment
US10610529B2 (en) *	2016-02-04	2020-04-07	Jiangsu Hengrui Medicine Co., Ltd.	Trabectedin-inclusive injectable pharmaceutical composition for gastrointestinal external use and a method for manufacturing the same
JOP20190254A1 (en)	2017-04-27	2019-10-27	Pharma Mar Sa	Antitumoral compounds
WO2020239478A1 (en)	2019-05-28	2020-12-03	Pharma Mar, S.A.	Trabectedin for treating sarcomas based on genomic markers
CN112574234B (en) *	2019-09-27	2022-05-24	江苏恒瑞医药股份有限公司	Preparation method of ecteinascidin derivative
WO2021209545A1 (en)	2020-04-15	2021-10-21	Ever Valinject Gmbh	Composition comprising trabectedin and an amino acid
EP3960177A1 (en) *	2020-08-26	2022-03-02	Anturec Pharmaceuticals GmbH	Composition comprising ttf-ngr for use in treating soft-tissue sarcoma
US12303506B2 (en)	2022-01-20	2025-05-20	Extrovis Ag	Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3774435D1 (en) *	1986-06-09	1991-12-12	Univ Pennsylvania	EKTEINASCIDINE 729, 743, 745, 759A, 759B AND 770.
US5256663A (en) *	1986-06-09	1993-10-26	The Board Of Trustees Of The University Of Illinois	Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en)	1990-11-30	1992-09-22	The Board Of Trustees Of The University Of Illinois	Ecteinascidins 736 and 722
US5089273A (en) *	1986-06-09	1992-02-18	Board Of Trustees Of The University Of Illinois	Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (en)	1986-10-21	1988-04-28	Knoll Ag	5-NITROBENZO (DE) ISOCHINOLIN-1,3-DIONE, THEIR PRODUCTION AND USE
GB8805268D0 (en) *	1988-03-04	1988-04-07	Glaxo Group Ltd	Medicaments
GB9101221D0 (en) *	1991-01-19	1991-02-27	Smithkline Beecham Plc	Pharmaceuticals
US5721352A (en)	1991-02-19	1998-02-24	University Of Florida Research Foundation	Entomopoxvirus expression system
FR2697752B1 (en)	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Antitumor compositions containing taxane derivatives.
US5891704A (en) *	1992-11-19	1999-04-06	Anticancer, Inc.	Method to produce high levels of methioninase
JPH09503743A (en) *	1993-05-14	1997-04-15	デポテックコーポレーション	How to treat neurological disorders
US5478932A (en) *	1993-12-02	1995-12-26	The Board Of Trustees Of The University Of Illinois	Ecteinascidins
US20040059112A1 (en)	1994-02-18	2004-03-25	Rinehart Kenneth L.	Ecteinascidins
US5919816A (en) *	1994-11-14	1999-07-06	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en)	1995-04-20	1995-06-07	Univ British Columbia	Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) *	1996-09-18	1998-02-24	President And Fellows Of Harvard College	Process for producing ecteinascidin compounds
WO1998019649A2 (en) *	1996-11-05	1998-05-14	The Children's Medical Center Corporation	Methods and compositions for inhibition of angiogenesis
IL123740A0 (en) *	1997-03-28	1998-10-30	Pfizer	NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en)	1997-04-15	1999-11-16	Univ Illinois	Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (en) *	1997-05-15	1998-11-19	Hoechst Ag	Preparation with increased in vivo tolerance
GB9801231D0 (en) *	1997-06-05	1998-03-18	Merck & Co Inc	A method of treating cancer
EP1876180A3 (en)	1998-04-06	2009-12-16	The Board Of Trustees Of The University Of Illinois	Semi-synthetic ecteinascidins
KR100643092B1 (en) *	1998-05-11	2006-11-10	파르마 마르, 에스.에이.	Metabolites of Etainincidin 743
US6124292A (en)	1998-09-30	2000-09-26	President And Fellows Of Harvard College	Synthetic analogs of ecteinascidin-743
MY164077A (en)	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
AR035842A1 (en)	1999-05-14	2004-07-21	Pharma Mar Sa	METHOD OF HEMISINTESIS FOR THE FORMATION OF INTERMEDIARY AND DERIVATIVE COMPOUNDS AND OF STRUCTURES RELATED TO ECTEINASCIDINE AND TETRAHYDROISOCHINOLINPHENOLS AND INTERMEDIARY APPLICATION COMPOUNDS IN SUCH METHOD
MXPA02010088A (en)	2000-04-12	2004-08-19	Pharma Mar Sa	Antitumoral ecteinascidin derivatives.
US7247892B2 (en)	2000-04-24	2007-07-24	Taylor Geoff W	Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (en)	2000-05-15	2003-06-06	Pharma Mar Sa	Antitumoral analogs of et 743.
US7420051B2 (en)	2000-05-15	2008-09-02	Pharma Mar, S.A.	Synthetic process for the manufacture of an ecteinaschidin compound
JP2004506430A (en)	2000-08-11	2004-03-04	シティ・オブ・ホープ	Inhibition of SXR-mediated transactivation by the anti-neoplastic agent ET-743
BR0115162A (en)	2000-11-06	2003-10-21	Pharma Mar Sa	Effective antitumor treatments
EP1360337A1 (en)	2001-02-09	2003-11-12	The Regents Of The University Of California	Ecteinascidin family compounds: compositions and methods
US20030027799A1 (en)	2001-03-30	2003-02-06	Shire Biochem Inc.	Methods of treating cancer using a combination of drugs
GB0121285D0 (en)	2001-09-03	2001-10-24	Cancer Res Ventures Ltd	Anti-cancer combinations
EP1435988A4 (en)	2001-10-19	2008-01-09	Pharmamar Sa	Improved use of antitumoral compound in cancer therapy
US20040019027A1 (en)	2002-04-12	2004-01-29	Barry Forman	Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en)	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
GB0324201D0 (en)	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
PT1689404E (en)	2003-11-13	2008-12-15	Pharma Mar Sau	Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
GB0326486D0 (en)	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
US20080255132A1 (en)	2003-11-14	2008-10-16	Eric Rowinsky	Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
JP2008505862A (en)	2004-07-09	2008-02-28	ファルマ、マール、ソシエダード、アノニマ	Prognostic molecular marker
JP2008514688A (en)	2004-09-29	2008-05-08	ファルマ・マル・エス・アー，ソシエダッド・ユニペルソナル	Etainacidin compounds as anti-inflammatory agents
PL1827500T3 (en)	2004-10-26	2009-09-30	Pharma Mar Sa	Pegylated liposomal doxorubicin in combination with ecteinescidin 743
DK1658848T3 (en)	2004-10-29	2007-11-26	Pharma Mar Sa	Formulations comprising ecteinascidin and a disaccharide
CA2630900A1 (en)	2005-11-25	2007-05-31	University Of Medicine And Dentistry Of New Jersey	Use of parp-1 inhibitors
EP2023931A2 (en)	2006-05-12	2009-02-18	Pharma Mar S.A.	Anticancer treatments with a combination of docetaxel and ecteinascidin

2000
- 2000-05-13 MY MYPI20002107A patent/MY164077A/en unknown
- 2000-05-15 PL PL352931A patent/PL198185B1/en unknown
- 2000-05-15 SI SI200031067T patent/SI1716853T1/en unknown
- 2000-05-15 ES ES06011784T patent/ES2294756T3/en not_active Expired - Lifetime
- 2000-05-15 AT AT06014005T patent/ATE500830T1/en active
- 2000-05-15 SI SI200030905T patent/SI1176964T1/en unknown
- 2000-05-15 ES ES00927584T patent/ES2272279T3/en not_active Expired - Lifetime
- 2000-05-15 CN CNB2005100091622A patent/CN100477993C/en not_active Expired - Lifetime
- 2000-05-15 IL IL14643400A patent/IL146434A0/en active IP Right Grant
- 2000-05-15 TR TR2001/03819T patent/TR200103819T2/en unknown
- 2000-05-15 PT PT06014005T patent/PT1716853E/en unknown
- 2000-05-15 EP EP00927584A patent/EP1176964B8/en not_active Expired - Lifetime
- 2000-05-15 AT AT06011784T patent/ATE375795T1/en active
- 2000-05-15 CN CN00809976A patent/CN1360503A/en active Pending
- 2000-05-15 AU AU45975/00A patent/AU777417B2/en not_active Expired
- 2000-05-15 DK DK06014005.0T patent/DK1716853T3/en active
- 2000-05-15 MX MXPA01011562A patent/MXPA01011562A/en active IP Right Grant
- 2000-05-15 KR KR1020017014479A patent/KR20020019914A/en not_active Ceased
- 2000-05-15 NZ NZ515423A patent/NZ515423A/en not_active IP Right Cessation
- 2000-05-15 DK DK06011784T patent/DK1702618T3/en active
- 2000-05-15 CA CA002373794A patent/CA2373794C/en not_active Expired - Lifetime
- 2000-05-15 AR ARP000102321A patent/AR028476A1/en not_active Application Discontinuation
- 2000-05-15 DK DK00927584T patent/DK1176964T3/en active
- 2000-05-15 DE DE122008000013C patent/DE122008000013I1/en active Pending
- 2000-05-15 PT PT00927584T patent/PT1176964E/en unknown
- 2000-05-15 DE DE60030554T patent/DE60030554T8/en active Active
- 2000-05-15 PT PT06011784T patent/PT1702618E/en unknown
- 2000-05-15 DE DE60045720T patent/DE60045720D1/en not_active Expired - Lifetime
- 2000-05-15 SI SI200030977T patent/SI1702618T1/en unknown
- 2000-05-15 AT AT00927584T patent/ATE338552T1/en active
- 2000-05-15 JP JP2000617900A patent/JP2002544231A/en not_active Withdrawn
- 2000-05-15 WO PCT/GB2000/001857 patent/WO2000069441A1/en not_active Ceased
- 2000-05-15 BR BR0010531-7A patent/BR0010531A/en not_active Application Discontinuation
- 2000-05-15 EP EP06014005A patent/EP1716853B9/en not_active Expired - Lifetime
- 2000-05-15 CZ CZ20014081A patent/CZ301482B6/en not_active IP Right Cessation
- 2000-05-15 HU HU0201187A patent/HU229866B1/en active Protection Beyond IP Right Term
- 2000-05-15 SK SK1644-2001A patent/SK287580B6/en not_active IP Right Cessation
- 2000-05-15 EP EP06011784A patent/EP1702618B1/en not_active Expired - Lifetime
- 2000-05-15 UA UA2001128559A patent/UA74782C2/en unknown
- 2000-05-15 DE DE60036826T patent/DE60036826T2/en not_active Expired - Lifetime
2001
- 2001-11-11 IL IL146434A patent/IL146434A/en active Protection Beyond IP Right Term
- 2001-11-12 NO NO20015516A patent/NO324564B1/en not_active IP Right Cessation
- 2001-12-03 BG BG106171A patent/BG65680B1/en unknown
2005
- 2005-01-14 AU AU2005200180A patent/AU2005200180B9/en not_active Expired
2006
- 2006-11-30 CY CY20061101734T patent/CY1105818T1/en unknown
2007
- 2007-06-28 US US11/769,873 patent/US8119638B2/en not_active Expired - Fee Related
2008
- 2008-01-16 CY CY20081100059T patent/CY1107143T1/en unknown
- 2008-02-22 NL NL300337C patent/NL300337I2/en unknown
- 2008-03-10 LU LU91418C patent/LU91418I2/en unknown
- 2008-04-07 CY CY200800007C patent/CY2008007I1/en unknown
- 2008-04-16 FR FR08C0013C patent/FR08C0013I2/en active Active
- 2008-05-16 NO NO2008005C patent/NO2008005I1/en not_active IP Right Cessation
2011
- 2011-06-08 CY CY20111100545T patent/CY1112753T1/en unknown
2012
- 2012-05-02 JP JP2012105249A patent/JP5777562B2/en not_active Expired - Lifetime
2015
- 2015-01-06 HU HUS1500001C patent/HUS1500001I1/en unknown

Also Published As

Publication number	Publication date
AU2005200180B2 (en)	2007-12-13
DE60036826D1 (en)	2007-11-29
ES2272279T3 (en)	2007-05-01
CN1360503A (en)	2002-07-24
IL146434A (en)	2008-03-20
EP1176964B8 (en)	2007-10-10
HUP0201187A2 (en)	2002-09-28
CA2373794A1 (en)	2000-11-23
IL146434A0 (en)	2002-07-25
AU4597500A (en)	2000-12-05
ES2294756T3 (en)	2008-04-01
JP5777562B2 (en)	2015-09-09
CZ20014081A3 (en)	2002-11-13
AR028476A1 (en)	2003-05-14
EP1716853A3 (en)	2006-11-15
AU2005200180B9 (en)	2008-05-29
US8119638B2 (en)	2012-02-21
PT1716853E (en)	2011-05-12
JP2012149095A (en)	2012-08-09
CY2008007I2 (en)	2009-11-04
PL198185B1 (en)	2008-06-30
LU91418I9 (en)	2019-01-02
EP1702618A3 (en)	2006-12-27
ATE338552T1 (en)	2006-09-15
BR0010531A (en)	2002-06-04
DE60030554T8 (en)	2008-01-10
EP1716853B1 (en)	2011-03-09
HUP0201187A3 (en)	2002-11-28
HU229866B1 (en)	2014-10-28
AU2005200180A1 (en)	2005-02-10
DE60030554D1 (en)	2006-10-19
CY2008007I1 (en)	2009-11-04
EP1716853A2 (en)	2006-11-02
EP1702618A2 (en)	2006-09-20
NO2008005I1 (en)	2008-06-09
JP2002544231A (en)	2002-12-24
DE60036826T2 (en)	2008-08-28
ATE375795T1 (en)	2007-11-15
MXPA01011562A (en)	2002-07-30
KR20020019914A (en)	2002-03-13
DE60030554T2 (en)	2007-09-13
BG65680B1 (en)	2009-06-30
CY1112753T1 (en)	2016-02-10
CZ301482B6 (en)	2010-03-17
ATE500830T1 (en)	2011-03-15
NO2008005I2 (en)	2010-09-27
CN1679631A (en)	2005-10-12
NL300337I2 (en)	2008-09-01
BG106171A (en)	2002-06-28
EP1716853B9 (en)	2011-09-28
CY1107143T1 (en)	2010-07-28
UA74782C2 (en)	2006-02-15
SI1716853T1 (en)	2011-10-28
CN100477993C (en)	2009-04-15
CA2373794C (en)	2005-10-11
NL300337I1 (en)	2008-05-01
EP1176964A1 (en)	2002-02-06
SK16442001A3 (en)	2002-03-05
DE60045720D1 (en)	2011-04-21
NZ515423A (en)	2004-04-30
FR08C0013I1 (en)	2008-05-30
DK1716853T3 (en)	2011-06-27
AU777417B2 (en)	2004-10-14
SK287580B6 (en)	2011-03-04
NO324564B1 (en)	2007-11-19
EP1176964B1 (en)	2006-09-06
LU91418I2 (en)	2008-05-13
HUS1500001I1 (en)	2016-08-29
EP1702618B1 (en)	2007-10-17
PT1702618E (en)	2008-01-11
FR08C0013I2 (en)	2009-10-30
US20070275942A1 (en)	2007-11-29
TR200103819T2 (en)	2002-04-22
MY164077A (en)	2017-11-30
DK1176964T3 (en)	2007-01-15
DK1702618T3 (en)	2008-02-25
PT1176964E (en)	2007-01-31
DE122008000013I1 (en)	2008-08-07
NO20015516D0 (en)	2001-11-12
NO20015516L (en)	2002-01-11
WO2000069441A1 (en)	2000-11-23
SI1176964T1 (en)	2007-02-28
PL352931A1 (en)	2003-09-22
CY1105818T1 (en)	2011-02-02

Publication	Publication Date	Title
HUS1500001I1 (en)	2016-08-29	Use of et743 in combination therapy with dexamethasone for treating cancer
GB2354949B (en)	2003-10-22	Apparatus for treating body tissues with electricty
PL370029A1 (en)	2005-05-16	2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
PL329947A1 (en)	1999-04-26	Baloon catheter for use in photodynamic therapy
KR100510795B1 (en)	2005-08-30	Compositions and Methods for the Treatment of Tumor
IL136167A0 (en)	2001-05-20	Conjugates useful in the treatment of prostate cancer
IL124650A0 (en)	1998-12-06	Methods and therapeutic compositions for treating cancer
HUP0200805A3 (en)	2004-07-28	Improved cancer treatment with temozolomide
EG22346A (en)	2002-12-31	Process for the preparation of conjugates useful in the treatment of prostate cancer
HUP0200717A3 (en)	2004-11-29	Radioactive cisplatin in the treatment of cancer
IL149281A0 (en)	2002-11-10	Treatment of cancer
PL352681A1 (en)	2003-09-08	Preventive and therapeutic agents for cancer
GB9906130D0 (en)	1999-05-12	Compounds for use in therapy
AU4486500A (en)	2000-11-10	Therapeutic compositions and methods for treating tumors
KR100511819B1 (en)	2005-09-02	Compositions and Methods for the Treatment of Tumor
GB2388548B (en)	2004-01-14	Apparatus for treating body tissues with medicaments
AU3735100A (en)	2000-10-09	Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
GB9905307D0 (en)	1999-04-28	Therapy and use of compounds in therapy
GB9905315D0 (en)	1999-04-28	Therapy and use of compounds in therapy
KR100526723B1 (en)	2005-11-09	Compositions and Methods for the Treatment of Tumor
KR100512820B1 (en)	2005-09-07	Compositions and Methods for the Treatment of Tumor
GB0022216D0 (en)	2000-10-25	Human FAP-a-specific antibodies for use in cancer therapy
GB9927106D0 (en)	2000-01-12	Cancer treatment
GB9908176D0 (en)	1999-06-02	Cancer treatment
GB9718160D0 (en)	1997-10-29	Conjugates useful in the treatment of prostate cancer